Efanesoctocog Alfa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Efanesoctocog Alfa. Educational only — not medical advice.
Labeled uses
ALTUVIIIO is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for: Routine prophylaxis to reduce the frequency of bleeding episodes On-demand treatment and control of bleeding episodes Perioperative management of bleeding
Source: FDA labeling via NIH DailyMed (set 01411972…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.